Literature DB >> 1404153

Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia.

A J Porges1, S L Beattie, C Ritchlin, R P Kimberly, C L Christian.   

Abstract

We describe 6 cases of patients with systemic lupus erythematosus (SLE) who developed Pneumocystis carinii pneumonia. All were treated with high dose corticosteroids, and all developed the infection within 4 months of beginning new or revised cytotoxic therapy. All patients tested (5 of 6) were negative for human immunodeficiency virus (HIV). Those patients who developed Pneumocystis carinii pneumonia had more severe lymphocytopenia (median 595 vs 833/mm3) and received higher doses of corticosteroids (median prednisone dose = 43 vs 20 mg/day) than other patients with active SLE. A threshold lymphocyte count of 350/mm3 identified 4 of 6 cases but only 1 of 20 controls. Patients with SLE treated with high dose corticosteroids and cytotoxic drugs and with severe lymphocytopenia may be at increased risk for this opportunistic infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1404153

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

1.  Prophylactic use of antibiotics and immunisations in patients with SLE.

Authors:  W R Gilliland; G C Tsokos
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

2.  Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.

Authors:  Philip N Okafor; Francis A Farraye; Adetoro T Okafor; Daniel O Erim
Journal:  Dig Dis Sci       Date:  2015-07-16       Impact factor: 3.199

Review 3.  Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?

Authors:  Rachel M Wolfe; James E Peacock
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

4.  Factors associated with Pneumocystis carinii pneumonia in Wegener's granulomatosis.

Authors:  B Godeau; J L Mainardi; F Roudot-Thoraval; E Hachulla; L Guillevin; L T Huong Du; B Jarrousse; P Remy; A Schaeffer; J C Piette
Journal:  Ann Rheum Dis       Date:  1995-12       Impact factor: 19.103

Review 5.  Complications of cyclophosphamide therapy.

Authors:  C A Langford
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

Review 6.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

7.  Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus.

Authors:  Ratchaya Lertnawapan; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2008-09-25       Impact factor: 2.631

Review 8.  Diagnosis and management of infectious complications of childhood rheumatic diseases.

Authors:  Rhina D Castillo; Wendy De la Pena; Katherine A B Marzan
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

9.  Long-Term Trends in Esophageal Candidiasis Prevalence and Associated Risk Factors with or without HIV Infection: Lessons from an Endoscopic Study of 80,219 Patients.

Authors:  Yuta Takahashi; Naoyoshi Nagata; Takuro Shimbo; Takeshi Nishijima; Koji Watanabe; Tomonori Aoki; Katsunori Sekine; Hidetaka Okubo; Kazuhiro Watanabe; Toshiyuki Sakurai; Chizu Yokoi; Masao Kobayakawa; Hirohisa Yazaki; Katsuji Teruya; Hiroyuki Gatanaga; Yoshimi Kikuchi; Sohtaro Mine; Toru Igari; Yuko Takahashi; Akio Mimori; Shinichi Oka; Junichi Akiyama; Naomi Uemura
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

Review 10.  Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention.

Authors:  Evin Sowden; Andrew J Carmichael
Journal:  BMC Infect Dis       Date:  2004-10-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.